Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose: An open-label, multicentre, non-comparative phase II trial to determine the response rate of intravenous vinflunine as first line chemotherapy in patients with metastatic renal cell carcinoma (RCC). Patients and methods: Patients with metastatic RCC were treated with vinflunine 350 mg/m2 (n = 11) or 320 mg/m2 (n = 22) administered intravenously every 21 days. Results: Out of 33 patients included in this study, one partial response was observed in the group treated at 350 mg/m2 and none in the group receiving 320 mg/m2 resulting in a response rate in this population of 9.1% (95% CI: 0.2–41.3). Median progression free survival was 5.6 months (95% CI: 2.8–14.4) for patients treated at 350 mg/m2, and 3.3 months (95% CI: 1.6–6.4) for those treated at 320 mg/m2.The median survival time was 10.4 months (95% CI: 6.8–12.4) for the whole study population. The principal toxicities were grade 3/4 neutropaenia —90.9% at 350 mg/m2 and 68.1% at 320 mg/m2, febrile neutropaenia was recorded in 3 patients (27.3%) at 350 mg/m2 and in 5 patients (22.7%) at 320 mg/m2. One episode of thromboembolic event was reported in 1 patient at each dose level. Conclusion: Vinflunine given intravenously once every 3 weeks has not shown any clinically relevant activity in the management of patients with metastatic renal cell carcinoma; tolerance of the treatment was better at a dose of 320 mg/m2 than at 350 mg/m2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417

    Article  PubMed  CAS  Google Scholar 

  2. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935

    PubMed  CAS  Google Scholar 

  3. Yang JC, Haworth L, Sherry RM, et al (2003) A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23:4508

    Google Scholar 

  5. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23:LBA4510

    Google Scholar 

  6. Pyrhönen S, Salminen E, Lehtonen T, et al. (1999) Prospective randomized trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cancer. J Clin Oncol 17:2859–2867

    PubMed  Google Scholar 

  7. Hill BT, Fiebig HH, Waud WR, et al. (1999) Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35:512–520

    Article  PubMed  CAS  Google Scholar 

  8. Bennouna J, Fumoleau P, Armand J-P, Raymond E, Campone M, Delgado F-M, Puozzo C, Marty M (2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14:630–637

    Article  PubMed  CAS  Google Scholar 

  9. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investigational New Drugs 10:239–253

    Article  PubMed  CAS  Google Scholar 

  10. WHO Handbook for reporting results for cancer treatment, Geneva: World Health Organisation, 1979

  11. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–151

    PubMed  CAS  Google Scholar 

  12. Weber BL, Vogel C, Jones S, et al. (1995) Intravenous vinorelbine as first line and second line therapy in advanced breast cancer. J Clin Oncol 13:2722–2730

    PubMed  CAS  Google Scholar 

  13. Rini B, Vogelzang NJ, Dumas MC, Wadell JL, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluororuracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426

    PubMed  CAS  Google Scholar 

  14. Waters JS, Moss C, Pyle L, James M, Hackett S, A’Hern R, Gore M, Eisen T (2004) Phase II clinical trial of capecitabine and gemcitabine in patients with metastatic renal carcinoma. Br J Cancer 91:1763–1768

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prince of Wales Hospital, Randwick, Australia

    D. Goldstein

  2. Mater Misericordiae Hospital, Waratah, Australia

    S. P. Ackland

  3. Royal North Shore Hospital, St. Leonards, Australia

    D. R. Bell

  4. Royal Adelaide Hospital, Adelaide, Australia

    I. N. Olver

  5. Austin Health, Heidelberg, Australia

    I. D. Davis

  6. Royal Melbourne Hospital, Parkville, Australia

    M. A. Rosenthal

  7. Peter Mac Callum Cancer Centre, East Melbourne, Australia

    G. C. Toner

  8. Institut de Recherche Pierre Fabre, Boulogne Billancourt, France

    M. C. Pinel

  9. Sir Charles Gairdner Hospital, Nedlands, Australia

    M. Byrne

Authors
  1. D. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. P. Ackland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. R. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. N. Olver
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. D. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. A. Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. C. Toner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. C. Pinel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Goldstein.

Additional information

Supported by Institute de Recherche Pierre Fabre Oncologie, Boulogne-Billancourt, France.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldstein, D., Ackland, S.P., Bell, D.R. et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs 24, 429–434 (2006). https://doi.org/10.1007/s10637-006-6437-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-006-6437-0

Keywords

Search

Navigation